Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer

Alessandra Metelli(MUSC Hollings Cancer Center), Mohammad Salem(MUSC Hollings Cancer Center), Caroline Wallace(MUSC Hollings Cancer Center), Bill X. Wu(Medical University of South Carolina), Anqi Li(MUSC Hollings Cancer Center), Xue Li(Boston Children's Hospital), Zihai Li(First Affiliated Hospital of Zhengzhou University)
Journal of Hematology & Oncology
February 20, 2018
Cited by 104Open Access
Full Text

Abstract

GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. GARP regulates the availability of membrane-bound latent TGF-β and modulates its activation. For this reason, GARP expression on immune and non-immune cells is involved in maintaining peripheral tolerance. It plays an important role in preventing inflammatory diseases such as allergy and graft versus host disease (GvHD). GARP is also frequently hijacked by cancer cells to promote oncogenesis. This review summarizes the most important features of GARP biology described to date including gene regulation, protein expression and mechanism in activating latent TGF-β, and the function of GARP in regulatory T cell biology and peripheral tolerance, as well as GARP’s increasingly recognized roles in platelet-mediated cancer immune evasion. The promise for GARP-targeted strategy as a novel immunotherapy of cancer is also highlighted.


Related Papers

No related papers found

Powered by citation graph analysis